Neurocognitive Driving Rehabilitation in Virtual Environments (NeuroDRIVE) as an Adjunctive Intervention for Traumatic Brain Injury
NCT ID: NCT02411227
Last Updated: 2020-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
37 participants
INTERVENTIONAL
2015-04-07
2020-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- People with traumatic brain injury (TBI) can have problems with thinking and everyday activities. They may have a higher risk for car accidents. NeuroDRIVE uses a virtual reality driving simulator. Researchers think it can help test and improve how people think and drive after TBI.
Objective:
\- To test how NeuroDRIVE affects brain performance and driving safety.
Eligibility:
\- People at least 18 years old with a history of TBI and who had a driver s license at some point. They must speak, read, and write English and be physically able to drive.
Design:
* Participants will be asked to release their driving records, but they do not have to do this to be in the study.
* Visit 1: Screening physical exam.
* Visit 2: Magnetic resonance imaging (MRI) scan. Participants will lie on a table that slides into a cylinder with a strong magnetic field. A device will be placed over the head. Participants may do computer tasks during the scan.
* Participants will have tests of memory, attention, and thinking. They may be asked questions, take tests, and do simple actions.
* Visit 3: Tests of memory, attention, and thinking, plus a virtual reality driving assessment.
* Participants will be assigned to Group 1 to start NeuroDRIVE training immediately or Group 2 to start 10 weeks later.
* Visits 4 9, over 4 weeks:
* Participants will practice driving skills and mental exercises in the simulator.
* They will complete a driving questionnaire online each week.
* Visit 10: Repeat of Visit 3, with some small changes.
* Visits 11-12: Very similar to Visits 1-2. Includes MRI scan; physical exam; questionnaires; and tests of thinking, memory, and attention..
* After Visit 12: Participants will fill out a weekly driving survey online for 4 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating the Efficacy of an Augmented Virtual Reality Driving Simulator on Institutionalized Dementia Patients
NCT06419257
The Development of a Virtual Reality Program to Improve Attention in Individuals With TBI
NCT03605017
Remote Stimulation and Training to Advance Recovery From TBI in Seniors
NCT07332299
Driver Training After Stroke
NCT06672107
Virtual Reality Treadmill Training in Individuals With Traumatic Brain Injury
NCT05721209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of this study is to evaluate the NeuroDRIVE behavioral intervention for enhancement of driving abilities, cognitive abilities, and neurobehavioral symptoms after traumatic brain injury (TBI). For the purposes of this protocol, NeuroDRIVE refers to the novel combined approach of driving training and cognitive rehabilitation in a virtual reality environment. While NeuroDRIVE utilizes the VR system as the method through which the intervention is administered, NeuroDRIVE is not the VR system itself.
STUDY POPULATION:
30 adult patients with a history of mild TBI and 30 adult patients with a history of moderate-to-severe TBI. Participants will be recruited from the National Institutes of Health (NIH), WRNMMC, and the broader community.
DESIGN:
The current study is a Clinical Trial Phase II interventional research study. The primary purpose of the study is for treatment, and it will employ a parallel intervention model. There will be no masking (i.e., open label). Participants will be classified into two groups by TBI severity: those with history of mild TBI and those with history of moderate-tosevere TBI. These different severities are known to have distinct cognitive sequelae. Within each severity group, participants will be in a 2 (pre-post) x 2 (treatment vs. wait list) experimental design.
OUTCOME MEASURES:
Primary outcome measures will include:
* Results from the Virtual Reality Driving Assessment (baseline and postintervention Tactical scenario composite scores)
* Total scores on the Neurobehavioral Symptom Inventory
* Standard and scaled scores from the following cognitive assessments (from the TBI Common Data Elements identified by NINDS):
WAIS-IV or WMS-IV Digit Span subtest
WAIS-IV Digit-Symbol Coding subtest
Secondary outcome measures will include:
-Neuroimaging results:
Regions of Interest for FMRI: Bilateral dorsolateral prefrontal cortex
Regions of Interest for DTI: Corpus callosum, bilateral frontal white matter horns, and bilateral longitudinal fasciculi
-Total scores on the following symptom questionnaires:
Glasgow Outcome Scale-Extended (GOS-E)
Ohio State University TBI Identification Method
Brief Symptom Inventory- 18
Satisfaction with Life Scale (SWLS)
PTSD Checklist- Civilian (PCL-C)
SF-36v2 Health Survey (SF-36v2)
Fatigue Severity Scale (FSS)
Epworth Sleepiness Scale (ESS)
Beck Depression Inventory-II (BDI-II)
Combat Exposure Scale (CES)
Dual Dangerous Driving Index (DDDI)
-Standard and scaled scores from the following cognitive phenotyping assessments (from the TBI Common Data Elements identified by NINDS):
California Verbal Learning Test- Second Edition (CVLT-II)
WAIS-IV Symbol Search subtest
Medical Symptom Validity Test (MSVT)
-Standard and scaled scores from the following additional cognitive phenotyping assessments:
Trail Making Test (TMT)
Test of Premorbid Functioning (ToPF)
Grooved Pegboard
Controlled Oral Word Association Test (COWAT)
Bethesda Eye and Attention Measure (BEAM)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Immediate Intervention
VR Driving
Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
2
Wait list
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VR Driving
Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Currently has a valid driver s license, or had a valid driver s license prior to injury
2. 18 years of age or older
3. Able to effectively manipulate the steering wheel and the gas/brake pedals without adaptive equipment
4. Able to read, write, and speak in English
5. History of traumatic brain injury greater than 12 weeks prior to initiation into the current study
6. Able to provide informed consent
7. NBSI score greater than or equal to 16 (Mild TBI sub-group only)
2. Alternatively, the participants can also fax their medical records to a secured fax machine at the Recreational Therapy office at the NIH where access is only permitted to study staff (i.e., scheduler, physician, and nurse psychologist).
3. Participants may also fill out a medical release document and submit it to the study coordinator.
As a condition of receiving funding from CNRM, de-identified imaging and phenotyping data (i.e., neurocognitive test results and behavioral questionnaires) from funded studies must be made available within a centralized repository (the CNRM Informatics Core) one year after the completion of the study. This is intended to facilitate use and analysis of this data for future research questions or projects. As such, potential subjects will be informed that they should not participate in this study if they do not want their data used for other projects.
Exclusion Criteria
1. Risk for injury from the MRI magnet, including:
* Pacemakers or other implanted electrical devices.
* Brain stimulators.
* Some types of dental implants.
* Aneurysm clips (metal clips on the wall of a large artery).
* Metallic prostheses (including metal pins and rods, heart valves, and cochlear implants).
* Permanent eyeliner (other non-metallic tattoos are permissible).
* Implanted delivery pump.
* Shrapnel fragments.
* Welders and metal workers are also at risk for injury because of possible small metal fragments in the eye of which they may be unaware.
* Fear of confined spaces.
* Back problems that may result in back pain or discomfort from lying in the scanner.
* Weight of over 350 pounds, due to the weight limit of the MRI table.
* It is not known if MRI is completely safe for a developing fetus. Therefore, all women of childbearing potential will have a pregnancy test performed no more than 24 hours before each MRI scan. The scan will not be done if the pregnancy test is positive. Because neuroimaging is a key component of the current study, inability to participate in MRI scanning is a necessary exclusion criterion.
2. History of penetrating brain injury
3. History of serious medical condition other than TBI that could affect cognitive or motor abilities (e.g., multiple sclerosis, encephalitis, cerebrovascular disease)
4. History of severe motion sickness and/or vertigo.
5. Other medical or psychological instability that could create difficulty fulfilling the study requirements (e.g., untreated mental illness, auditory/visual hallucinations, narcolepsy)
To verify this information, study coordinators will request medical records (i.e., recent medical history, medication list, any neuroimaging, and records pertinent to the participant s recent injury) to further evaluate potential participants inclusion into the study. Medical records can be obtained in three ways:
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Center for Neuroscience and Regenerative Medicine (CNRM)
UNKNOWN
Uniformed Services University of the Health Sciences
FED
National Institutes of Health Clinical Center (CC)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leighton Chan, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institutes of Health Clinical Center (CC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ortoleva C, Brugger C, Van der Linden M, Walder B. Prediction of driving capacity after traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2012 Jul-Aug;27(4):302-13. doi: 10.1097/HTR.0b013e3182236299.
Cox DJ, Davis M, Singh H, Barbour B, Nidiffer FD, Trudel T, Mourant R, Moncrief R. Driving rehabilitation for military personnel recovering from traumatic brain injury using virtual reality driving simulation: a feasibility study. Mil Med. 2010 Jun;175(6):411-6. doi: 10.7205/milmed-d-09-00081.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-CC-0103
Identifier Type: -
Identifier Source: secondary_id
150103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.